OTCMKTS:SGIOY Shionogi & Co., Ltd. Unsponsored ADR Earnings Date & Estimates $8.81 +0.13 (+1.50%) As of 03:55 PM Eastern Shionogi & Co., Ltd. Unsponsored ADR is estimated to report earnings on Monday, October 26, 2026, after market closes. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateOctober 26, 2026TimeAfter Market Closes Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Shionogi & Co., Ltd. Unsponsored ADRShionogi & Co., Ltd. Unsponsored ADR is expected to post earnings of $0.13 per share on revenue of $1.11 billion. In the same quarter a year earlier Shionogi & Co., Ltd. Unsponsored ADR reported $0.18 per share on revenue of $740.85 million. Shionogi & Co., Ltd. Unsponsored ADR last reported on August 3, 2026, posting $0.36 per share and beating the $0.18 consensus estimate. Shionogi & Co., Ltd. Unsponsored ADR has beaten the consensus EPS estimate in 5 of its last 7 quarters.Consensus EstimatesConsensus EPS$0.13Expected Revenue$1.11 billionPrior-Year EPS$0.18Prior-Year Revenue$740.85 millionExpected EPS Growth-27.8%Expected Revenue Growth+49.9%Recent Track RecordLast ReportedQ1 2027Last Quarter EPS$0.36 (Beat by +$0.18)Last Quarter Revenue$1.04 billionEPS Beat Rate5 of last 7 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ1 2027 Earnings ReportQ4 2026 Earnings ReportQ3 2026 Earnings Report Shionogi & Co., Ltd. Unsponsored ADR Earnings FAQ When does Shionogi & Co., Ltd. Unsponsored ADR report earnings? Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) is estimated to report earnings on Monday, October 26, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Shionogi & Co., Ltd. Unsponsored ADR? Analysts expect Shionogi & Co., Ltd. Unsponsored ADR to post earnings of $0.13 per share for the quarter. How much revenue is Shionogi & Co., Ltd. Unsponsored ADR expected to report? The consensus revenue estimate for Shionogi & Co., Ltd. Unsponsored ADR is $1.11 billion for the quarter. Shionogi & Co., Ltd. Unsponsored ADR Earnings HeadlinesShionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Shorted: Short Interest Down 97.4% in SeptemberOctober 11 at 1:00 PM | americanbankingnews.comContrasting Orion OYJ (OTCMKTS:ORINY) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)October 8, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 13 at 1:00 AM | Altimetry (Ad)Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) versus Tilray Brands (NASDAQ:TLRY) Head to Head AnalysisOctober 8, 2026 | americanbankingnews.comFinancial Survey: Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) & Lexaria Bioscience (NASDAQ:LEXX)October 6, 2026 | americanbankingnews.comAll You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to BuyFebruary 4, 2026 | msn.comSee More Shionogi & Co., Ltd. Unsponsored ADR Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shionogi & Co., Ltd. Unsponsored ADR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shionogi & Co., Ltd. Unsponsored ADR and other key companies, straight to your email. Email Address About Shionogi & Co., Ltd. Unsponsored ADRShionogi & Co., Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need. Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies. Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions. The company conducts research and development, manufacturing and commercialization activities through its own operations and collaborations with other pharmaceutical organizations.View Shionogi & Co., Ltd. Unsponsored ADR ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
